Keyword: Takeda

With the Shire deal done, Takeda is looking to lighten the load a little from its central R&D base. To that end, it has launched a new biotech, Phathom.

Eisai installs new Alzheimer's clinical leadership team; Insys founder found guilty in landmark opioid suit; and Gilead's chief plots Kite CEO hire.

Adimab is continuing a dealmaking streak with three more deal expansions, with Novartis, Regeneron and Takeda.

Skyhawk Therapeutics is teaming up with Takeda to develop small molecules that correct RNA mis-splicing in neurodegenerative disease.

Celgene will use Presage’s microdosing technology conduct phase 0 trials for cancer drugs.

Rare disease biotech Cyclerion has poached Shire’s ex-head of R&D, Andy Busch, Ph.D., as its new chief innovation officer, less than 18 months after he joined the company from his long stint at Bayer.

Appetite for biotech IPOs still appears high as Hookipa Pharma filed for a meaty public offering to boost its midstage cancer and infectious disease work.

T-cell startup Maverick Therapeutics has promoted Robert DuBridge and Chad May.

The deal gives Takeda a stake in a small molecule designed to disarm virulent bacteria and thereby treat gastrointestinal disorders.

Ex-Gilead CMO Andrew Cheng to lead Akero; Sanofi trades executives with Bayer in restructuring; and Crescendo names ex-Roche leader as CMO.